Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F ROLLAND

Showing results (121-130 of 124) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 124 results.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2017
Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastasesY Loriot, L Pagliaro, A Fléchon, et al.
ESMO Open|May 1, 2025
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)R Galot, C Le Tourneau, L Licitra, et al.
Bulletin Du Cancer|October 16, 2013
[Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC]J Thariat, F Jegoux, Y Pointreau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†A Kramar, S Negrier, R Sylvester, et al.
Pageof 13

Showing results (121-130 of 124) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 124 results.
European Journal of Cancer (Oxford, England : 1990)|November 18, 2017
Patterns of relapse in poor-prognosis germ-cell tumours in the GETUG 13 trial: Implications for assessment of brain metastasesY Loriot, L Pagliaro, A Fléchon, et al.
ESMO Open|May 1, 2025
A phase II study of monalizumab and durvalumab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck: results of the I2 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)R Galot, C Le Tourneau, L Licitra, et al.
Bulletin Du Cancer|October 16, 2013
[Advances in head and neck cancers on behalf of the French Intergroup ORL and GORTEC]J Thariat, F Jegoux, Y Pointreau, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2015
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†A Kramar, S Negrier, R Sylvester, et al.
Pageof 13